Remi Veillon
Bordeaux, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2025
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO.
Journal: JTO clinical and research reports
Published: November 14, 2025
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 17, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Journal: Clinical lung cancer
Published: April 21, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.
Journal: Targeted oncology
Published: February 03, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 26, 2024
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Journal: Clinical lung cancer
Published: November 17, 2024
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.
Journal: JTO clinical and research reports
Published: June 13, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 20, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2024
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.
Journal: Joint bone spine
Published: March 20, 2024
Last Updated: 09/26/2026